No Detail Found!

Effectiveness of HA330 hemoperfusion as an adjunctive therapy for severe COVID-19 patients: a single center experience

Author(s)
Atthaphong Phongphithakchai Nephrology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand
Pirun Saelue Clinical Hematology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University,Hat Yai, Songkhla 90110,Thailand
Suwikran Wongpraphairot Nephrology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University,Hat Yai, Songkhla 90110,Thailand
Ussanee Boonsrirat , Nephrology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University,Hat Yai, Songkhla 90110,Thailand
Abstract
Background & objective: Cytokine storms play a significant role in conditions leading to multi-organ failure in patients with severe corona virus disease-2019 (COVID-19). The eradication of pro-inflammatory cytokines through hemoperfusion has been suggested to be a possible strategy to improve outcomes in these patients. We evaluated the impact of adjunctive HA330 hemoperfusion on outcomes in severe COVID-19 patients. Methodology: A single-center retrospective cohort study was conducted from December 2021 to December 2022. We included severe COVID-19 patients with elevated pro-inflammatory markers, who received three consecutive sessions of HA330 hemoperfusion in addition to the standard treatment protocol. Clinical data, including demographic information, baseline characteristics, and treatment outcomes, were analyzed. Results: We evaluated 24 severe COVID-19 patients. We observed a significant reduction in levels of CRP (P < 0.001) and IL-6 (P = 0.042), as well as a significant increase in arterial partial pressure of oxygen (P = 0.041). Importantly, no patient experienced cytotoxicity after the HA330 hemoperfusion sessions, confirming the biocompatibility of the treatment. Conclusion: Three consecutive sessions of HA330 hemoperfusion, used as an adjunctive therapy to standard care in severe COVID-19 patients, effectively reduced pro-inflammatory cytokine levels and improved oxygenation. However, large multicenter trials are required to validate these clinical outcomes. 
Publication Details
Page(s) 265-271
Published Journal: Anaesthesia, Pain and Intensive Care, Volume: 28, Issue: 2, Year: 2024

Request the full text from PASTIC

Keywords
Cytokine, Hemoperfusion, Extracorporeal membrane oxygenation, Coronavirus Disease-2019
References
Dessie ZG,Zewotir T .2021 .Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis, 21(1) : 855.
.2023 .. Weekly epidemiological update on COVID-19 - 1 September, : .
. .. epidemiological-update-on-covid-19---1-september-2023, : .
.2015 .. , 33 : 823-874.
Zanza C,Romenskaya T,Manetti AC,Franceschi F,La Russa R,Bertozzi G . .. Medicina (Kaunas)., : .
.2022 .. PMID: 35208467 DOI: 10.3390/medicina58020144, 58(2) : .
.2020 .. , 383(23) : 2255-2273.
Huang C,Wang Y,Li X,Ren L,Zhao J,Hu Y .2020 .Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. , 6736(20) : 30183-5.
Zhu Z,Cai T,Fan L,Lou K,Hua X,Huang Z .2020 .Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis, 95 : 332-339.
.2020 .. PMID: 32334118 DOI: 10, 04 : .
Ruan Q,Yang K,Wang W,Jiang L,Song J. . .Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med., : .
.2020 .. , 46(5) : 846-848.
Ronco C,Bellomo R. Hemoperfusion C .2022 .: technical aspects and state of the art. Crit Care, 26(1) : 135.
Ankawi G,Fan W,Pomarè Montin D,Lorenzin A,Neri M,Caprara C .2019 .A New Series of Sorbent Devices for Multiple Clinical Purposes: Current Evidence and Future Directions. Blood Purif, 47(1-3) : 94-100.
Clark EG,Hiremath S,McIntyre L,Wald R,Hundemer GL,Joannidis M. .2020 .Haemoperfusion should only be used for COVID19 in the context of randomized trials. Nat Rev Nephrol, 16(12) : 697-699.
Mo P,Xing Y,Xiao Y,Deng L,Zhao Q,Wang H .2019 .. Clinical Characteristics of Refractory Coronavirus Disease, : .
Xie J,Covassin N,Fan Z,Singh P,Gao W,Li G .2020 .. Association Between Hypoxemia and Mortality in Patients With COVID-19. Mayo Clin Proc, 04(6) : 1138-1147.
Zhou F,Yu T,Du R,Fan G,Liu Y,Liu Z .2020 .Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 6736(20) : 30566-3.
Soleimani A,Taba SMM,Hasibi Taheri S,Loghman AH,Shayestehpour M. . .The effect of hemoperfusion on the outcome, clinical and laboratory findings of patients with severe COVID19: a retrospective study. New Microbes New Infect., : .
Peng JY,Li L,Zhao X,Ding F,Hou X .2022 .Hemoperfusion with CytoSorb® in Critically Ill COVID-. Patients. Blood Purif, 51(5) : 410-416.
Surasit K,Srisawat N. .2022 .The Efficacy of Early Additional Hemoperfusion Therapy for Severe COVID-19 Patients: A Prospective Cohort Study. Blood Purif, 51(11) : 879-888.
Pomarè Montin D,Ankawi G,Lorenzin A,Neri M,Caprara C .2018 .Biocompatibility and Cytotoxic Evaluation of New Sorbent Cartridges for Blood Hemoperfusion. Blood Purif, 46(3) : 187-195.
0

Citations

0

Downloads

35

Views